361 related articles for article (PubMed ID: 28851760)
21. Real-world outcomes and management strategies for venetoclax-treated chronic lymphocytic leukemia patients in the United States.
Mato AR; Thompson M; Allan JN; Brander DM; Pagel JM; Ujjani CS; Hill BT; Lamanna N; Lansigan F; Jacobs R; Shadman M; Skarbnik AP; Pu JJ; Barr PM; Sehgal AR; Cheson BD; Zent CS; Tuncer HH; Schuster SJ; Pickens PV; Shah NN; Goy A; Winter AM; Garcia C; Kennard K; Isaac K; Dorsey C; Gashonia LM; Singavi AK; Roeker LE; Zelenetz A; Williams A; Howlett C; Weissbrot H; Ali N; Khajavian S; Sitlinger A; Tranchito E; Rhodes J; Felsenfeld J; Bailey N; Patel B; Burns TF; Yacur M; Malhotra M; Svoboda J; Furman RR; Nabhan C
Haematologica; 2018 Sep; 103(9):1511-1517. PubMed ID: 29880613
[TBL] [Abstract][Full Text] [Related]
22. Venetoclax as a therapeutic option for the treatment of chronic lymphocytic leukemia: the evidence so far.
Held L; Siu C; Shadman M
Expert Opin Pharmacother; 2021 Apr; 22(6):655-665. PubMed ID: 33645381
[TBL] [Abstract][Full Text] [Related]
23. Venetoclax for the Treatment of Chronic Lymphocytic Leukemia.
Eradat H
Curr Hematol Malig Rep; 2019 Oct; 14(5):469-476. PubMed ID: 31512151
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome.
Cozad M; Stump SE; Buhlinger K; Collins J; Muir M; Coombs CC; Muluneh B
Leuk Lymphoma; 2022 Aug; 63(8):1831-1838. PubMed ID: 35262457
[TBL] [Abstract][Full Text] [Related]
25. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
26. Venetoclax: A novel B-cell lymphoma-2 inhibitor for chronic lymphocytic leukemia and other hematologic malignancies.
Olin JL; Griffiths CL; Smith MB
J Oncol Pharm Pract; 2018 Oct; 24(7):517-524. PubMed ID: 28696175
[TBL] [Abstract][Full Text] [Related]
27. Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy.
Coutre S; Choi M; Furman RR; Eradat H; Heffner L; Jones JA; Chyla B; Zhou L; Agarwal S; Waskiewicz T; Verdugo M; Humerickhouse RA; Potluri J; Wierda WG; Davids MS
Blood; 2018 Apr; 131(15):1704-1711. PubMed ID: 29305552
[TBL] [Abstract][Full Text] [Related]
28. Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.
Izutsu K; Yamamoto K; Kato K; Ishikawa T; Fukuhara N; Terui Y; Choi I; Humphrey K; Kim SY; Okubo S; Ogawa N; Nishimura Y; Salem AH; Maruyama D
Int J Hematol; 2021 Mar; 113(3):370-380. PubMed ID: 33094474
[TBL] [Abstract][Full Text] [Related]
29. Minimizing and managing treatment-associated complications in patients with chronic lymphocytic leukemia.
Iskierka-Jażdżewska E; Robak T
Expert Rev Hematol; 2020 Jan; 13(1):39-53. PubMed ID: 31747803
[No Abstract] [Full Text] [Related]
30. Novel agents in the treatment of chronic lymphocytic leukemia: a review about the future.
Desai AV; El-Bakkar H; Abdul-Hay M
Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):314-22. PubMed ID: 25445466
[TBL] [Abstract][Full Text] [Related]
31. Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.
Rogers KA; Huang Y; Ruppert AS; Awan FT; Heerema NA; Hoffman C; Lozanski G; Maddocks KJ; Moran ME; Reid MA; Lucas M; Woyach JA; Whitlow WT; Jones JA; Byrd JC
Blood; 2018 Oct; 132(15):1568-1572. PubMed ID: 30111609
[TBL] [Abstract][Full Text] [Related]
32. Tumor lysis syndrome risk in outpatient versus inpatient administration of venetoclax and hypomethlators for acute myeloid leukemia.
Pelcovits A; Moore J; Bakow B; Niroula R; Egan P; Reagan JL
Support Care Cancer; 2021 Sep; 29(9):5323-5327. PubMed ID: 33661367
[TBL] [Abstract][Full Text] [Related]
33. Obinutuzumab pretreatment abrogates tumor lysis risk while maintaining undetectable MRD for venetoclax + obinutuzumab in CLL.
Kater AP; Kersting S; van Norden Y; Dubois J; Dobber JA; Mellink CH; Evers LM; Croon-de Boer F; Schreurs J; van der Spek E; Visser H; Idink C; Wittebol S; Hoogendoorn M; Tonino SH; Mobasher M; Levin MD;
Blood Adv; 2018 Dec; 2(24):3566-3571. PubMed ID: 30552161
[TBL] [Abstract][Full Text] [Related]
34. [Targeted treatment of chronic lymphocytic leukaemia].
Niemann CU
Ugeskr Laeger; 2014 Apr; 176(15):. PubMed ID: 25350143
[TBL] [Abstract][Full Text] [Related]
35. Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia.
Davids MS; Hallek M; Wierda W; Roberts AW; Stilgenbauer S; Jones JA; Gerecitano JF; Kim SY; Potluri J; Busman T; Best A; Verdugo ME; Cerri E; Desai M; Hillmen P; Seymour JF
Clin Cancer Res; 2018 Sep; 24(18):4371-4379. PubMed ID: 29895707
[No Abstract] [Full Text] [Related]
36. Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Chronic Lymphocytic Leukemia: Ibrutinib, Idelalisib, and Venetoclax.
Waldron M; Winter A; Hill BT
Clin Pharmacokinet; 2017 Nov; 56(11):1255-1266. PubMed ID: 28343293
[TBL] [Abstract][Full Text] [Related]
37. Real-world outcomes following venetoclax therapy in patients with chronic lymphocytic leukemia or Richter syndrome: a FILO study of the French compassionate use cohort.
Bouclet F; Calleja A; Dilhuydy MS; Véronèse L; Pereira B; Amorim S; Cymbalista F; Herbaux C; de Guibert S; Roos-Weil D; Hivert B; Aurran T; Dupuis J; Blouet A; Tchernonog E; Laribi K; Dmytruck N; Morel P; Michallet AS; Dartigeas C; Tournilhac O; Nguyen-Khac F; Delmer A; Feugier P; Ysebaert L; Guièze R
Ann Hematol; 2021 Apr; 100(4):987-993. PubMed ID: 33495922
[TBL] [Abstract][Full Text] [Related]
38. Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.
García-Marco JA; Delgado J; Hernández-Rivas JA; Ramírez Payer Á; Loscertales Pueyo J; Jarque I; Abrisqueta P; Giraldo P; Martínez R; Yáñez L; Terol MJ; González M; Bosch F;
Med Clin (Barc); 2017 Apr; 148(8):381.e1-381.e9. PubMed ID: 28236475
[TBL] [Abstract][Full Text] [Related]
39. Recurrent chemotherapy-induced tumor lysis syndrome (TLS) with renal failure in a patient with chronic lymphocytic leukemia - successful treatment and prevention of TLS with low-dose rasburicase.
Hummel M; Buchheidt D; Reiter S; Bergmann J; Adam K; Hehlmann R
Eur J Haematol; 2005 Dec; 75(6):518-21. PubMed ID: 16313266
[TBL] [Abstract][Full Text] [Related]
40. Effective Tumor Debulking with Ibrutinib Before Initiation of Venetoclax: Results from the CAPTIVATE Minimal Residual Disease and Fixed-Duration Cohorts.
Barr PM; Tedeschi A; Wierda WG; Allan JN; Ghia P; Vallisa D; Jacobs R; O'Brien S; Grigg AP; Walker P; Zhou C; Ninomoto J; Krigsfeld G; Tam CS
Clin Cancer Res; 2022 Oct; 28(20):4385-4391. PubMed ID: 35939599
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
